Octagam® 10%

The First and Only FDA-Approved IVIg Therapy
for Dermatomyositis in Adults

Newly Approved Indication!

The U.S. Food and Drug Administration (FDA) has approved octagam 10% [Immune Globulin Intravenous (Human)] for the treatment of dermatomyositis (DM) in adults1, a rare, immune-mediated inflammatory disease.

FDA approval for the new indication was based on the results of ProDERM, a pivotal randomized clinical trial and the first to evaluate the long-term efficacy and safety of IVIg therapy for adults with DM.

Learn More

If you'd like to talk to an Octapharma Medical Science Liaison about octagam 10% and stay current on product updates, just complete and submit the form.

Keep Me Updated on Octagam

*Required fields

By submitting this form, you are consenting to receive future communications from Octapharma and/or an Octapharma representative. Please review our Privacy Policy.

References:

  1. Octagam 10% Full Prescribing Information. Paramus, NJ: Octapharma USA Inc; rev June 2021
GAM10-0239
Indications and Important Safety Information for octagam® 10% [Immune Globulin Intravenous (Human) 10% Liquid Preparation]
WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
Please see octagam 10% full Prescribing Information for complete boxed warning and other important information.